{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:50:29Z","timestamp":1790257829802,"version":"4.1.0"},"reference-count":26,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Transplantation"],"published-print":{"date-parts":[[2025,8]]},"abstract":"ABSTRACT<\/jats:title>\n \n Background<\/jats:title>\n Rabbit anti\u2010thymocyte globulin (r\u2010ATG) is a thymocyte depleting agent for the induction of immunosuppression in kidney transplant recipients (KTRs). There is little data comparing a level of CD3+ T\u2010cell suppression for optimal graft outcomes with minimized infectious risk.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n KTRs from January 2020 to January 2024 were included if they met these criteria: (1) <\u200921\u2009years of age at transplantation, (2) no previous receipt of a solid organ or hematopoietic stem cell transplant, (3) completion of a r\u2010ATG\u2010based induction protocol, (4) had absolute CD3+ T\u2010cell counts quantified at induction, and (5) at least 6\u2009months posttransplant follow\u2010up. Patients were grouped based on their CD3+ cell counts during or within 24\u2010h of induction (<\u200925\u2009cells\/mm\n 3<\/jats:sup>\n vs. \u2265\u200925\u2009cells\/mm\n 3<\/jats:sup>\n ) and statistical comparisons were made.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of 111 KTRs reviewed, 28 were included. A CD3+ cell count <\u200925 was achieved in 22\/28 (79%) recipients, following a median r\u2010ATG dose of 4.35\u2009mg\/kg (IQR: 3.00\u20134.55). The median age was 15\u2009years (IQR: 13.50\u201316.75). The median dose of r\u2010ATG administered by completion of induction was 4.530\u2009mg\/kg (IQR: 4.434\u20134.737) and did not differ between groups (\n p<\/jats:italic>\n \u2009=\u20090.758). There was no difference in the rate of rejection, infectious markers, or hospitalization based on CD3+ levels. There was no mortality or graft loss.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n There were no observed differences in post\u2010transplant outcomes when compared by CD3+. As the dose of r\u2010ATG delivered and outcomes were similar, monitoring of CD3+ T\u2010cell populations during induction may not be necessary.<\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/petr.70141","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T04:09:01Z","timestamp":1753157341000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Absolute\n CD3<\/scp>\n + T\u2010Cell Counts After Anti\u2010Thymocyte Globulin: Impact on Graft and Infectious Outcomes in Pediatric Kidney Recipients"],"prefix":"10.1111","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3904-983X","authenticated-orcid":false,"given":"Travis","family":"Churilla","sequence":"first","affiliation":[{"name":"Division of Pediatric Nephrology Ann & Robert H. Lurie Children's Hospital of Chicago Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8627-8964","authenticated-orcid":false,"given":"Natalia","family":"Panek","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Ann & Robert H. Lurie Children's Hospital of Chicago Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8836-0881","authenticated-orcid":false,"given":"Priya S.","family":"Verghese","sequence":"additional","affiliation":[{"name":"Division of Pediatric Nephrology Ann & Robert H. Lurie Children's Hospital of Chicago Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000295420.49063.b1"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/TXD.0000000000001042"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2021.01.007"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200205150-00025"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2013.02.092"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399\u20100012.2012.01656.x"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2021.101388"},{"key":"e_1_2_9_9_1","unstructured":"U.S. Food and Drug Administration \u201cThymoglobulin (Anti\u2010Thymocyte Globulin [Rabbit]) Prescribing Information \u201d(2024) https:\/\/www.accessdata.fda.gov."},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.10.047"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/petr.12193"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2020.01.290"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/petr.14077"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00467\u2010021\u201005407\u2010y"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399\u20103046.2005.00358.x"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/petr.13018"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00467\u2010018\u20103959\u20106"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.20213210S1605c"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/petr.14273"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/petr.14658"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/petr.13717"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000002191"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000787"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00467\u2010014\u20102866\u20108"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2012.02.003"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262\u2010021\u201001053\u20107"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471\u20102334\u201012\u2010128"}],"container-title":["Pediatric Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/petr.70141","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T12:37:06Z","timestamp":1764679026000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/petr.70141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1111\/petr.70141"],"URL":"https:\/\/doi.org\/10.1111\/petr.70141","archive":["Portico"],"relation":{},"ISSN":["1397-3142","1399-3046"],"issn-type":[{"value":"1397-3142","type":"print"},{"value":"1399-3046","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,21]]},"assertion":[{"value":"2025-04-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70141"}}